Zevra Therapeutics
ZVRA
40 hedge funds and large institutions have $29M invested in Zevra Therapeutics in 2016 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 12 increasing their positions, 10 reducing their positions, and 3 closing their positions.
20% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 10
17% more capital invested
Capital invested by funds: $24.8M → $29M (+$4.11M)
0% more funds holding
Funds holding: 40 → 40 (0)
0% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 3
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
Top Sellers
| 1 |
DM
Deerfield Management
New York
|
-$1.49M |
| 2 |
SIM
Spark Investment Management
New York
|
-$494K |
| 3 |
Millennium Management
New York
|
-$155K |
| 4 |
TC
TFS Capital
West Chester,
Pennsylvania
|
-$53K |
| 5 |
ProShare Advisors
Bethesda,
Maryland
|
-$43K |
ZVRA Hedge Fund Activity: Q3 2016 in Review
40 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Zevra Therapeutics (ZVRA) for Q3 2016, worth a combined $29M — up 17% from $24.8M a quarter earlier.
Fund positioning in ZVRA was balanced in Q3 2016: 3 funds opened new positions, 3 closed out, 12 added to existing stakes and 10 trimmed.
The largest buyer was Creative Planning, adding an estimated $1.79M. The largest seller was Deerfield Management, cutting an estimated $1.49M.
- 40 institutional investors held Zevra Therapeutics (ZVRA) as of Q3 2016, unchanged from Q2 2016.
- Funds reported $29M of Zevra Therapeutics stock for Q3 2016, up 17% quarter-over-quarter.
- 3 funds opened new Zevra Therapeutics positions in Q3 2016 and 3 closed out, a net change of 0 holders.
- The largest Zevra Therapeutics buyer in Q3 2016 was Creative Planning, an estimated $1.79M added.
- The largest Zevra Therapeutics seller in Q3 2016 was Deerfield Management, an estimated $1.49M sold.
Based on aggregated 13F filings for Q3 2016.